P53 Status as a Predictive Biomarker for Patients Receiving Neoadjuvant Radiation-Based Treatment: A Meta-Analysis in Rectal Cancer

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Chen, Min Bin ^a   Wu, Xiao Yang ^a   Yu, Rong ^b   Li, Chen ^c   Wang, Li Qiang ^a   Shen, Wei ^d   Lu, Pei Hua ^d  

^a KUNSHAN FIRST PEOPLE S HOSPITAL AFFILIATED TO JIANGSU UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^d WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P53;

ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CHEMORADIOTHERAPY; DISEASE ASSOCIATION; DISEASE MARKER; GENE MUTATION; HUMAN; OUTCOME ASSESSMENT; PREDICTION; PROTEIN EXPRESSION; PUBLICATION; RECTUM CANCER; SEQUENCE ANALYSIS; SYSTEMATIC ERROR; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; WILD TYPE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CHEMORADIOTHERAPY; GAMMA RAYS; GENE EXPRESSION; HUMANS; MUTATION; NEOADJUVANT THERAPY; NEOPLASM GRADING; PROGNOSIS; RECTAL NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84866636175     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045388     Document Type: Article

References (50)

1. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.
2. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, et al. (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345: 638-646.
3. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, et al. (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740.
4. Wong RK, Tandan V, De Silva S, Figueredo A (2007) Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev: CD002102.
5. Cuddihy AR, Bristow RG, (2004) The p53 protein family and radiation sensitivity: Yes or no? Cancer Metastasis Rev 23: 237-257.
6. Huerta S, Gao X, Saha D, (2009) Mechanisms of resistance to ionizing radiation in rectal cancer. Expert Rev Mol Diagn 9: 469-480.
7. Tewari M, Krishnamurthy A, Shukla HS, (2008) Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol 17: 301-311.
8. Vousden KH, Prives C, (2009) Blinded by the Light: The Growing Complexity of p53. Cell 137: 413-431.
9. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T, (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849.
10. Merritt AJ, Potten CS, Kemp CJ, Hickman JA, Balmain A, et al. (1994) The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 54: 614-617.
11. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, et al. (1996) Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 2: 1665-1671.
12. Shinto E, Hashiguchi Y, Ueno H, Kobayashi H, Ishiguro M, et al. (2011) Pretreatment CD133 and cyclooxygenase-2 expression as the predictive markers of the pathological effect of chemoradiotherapy in rectal cancer patients. Dis Colon Rectum 54: 1098-1106.
13. Chen Z, Duldulao MP, Li W, Lee W, Kim J, et al. (2011) Molecular diagnosis of response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer. J Am Coll Surg 212: 1008-1017 e1001.
14. Garcia VM, Batlle JF, Casado E, Burgos E, de Castro J, et al. (2011) Immunohistochemical analysis of tumour regression grade for rectal cancer after neoadjuvant chemoradiotherapy. Colorectal Dis 13: 989-998.
15. Brophy S, Sheehan KM, McNamara DA, Deasy J, Bouchier-Hayes DJ, et al. (2009) GLUT-1 expression and response to chemoradiotherapy in rectal cancer. Int J Cancer 125: 2778-2782.
16. Chen MF, Lee KD, Yeh CH, Chen WC, Huang WS, et al. (2010) Role of peroxiredoxin I in rectal cancer and related to p53 status. Int J Radiat Oncol Biol Phys 78: 868-878.
17. Kandioler D, Zwrtek R, Ludwig C, Janschek E, Ploner M, et al. (2002) TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer. Ann Surg 235: 493-498.
18. Luna-Perez P, Arriola EL, Cuadra Y, Alvarado I, Quintero A, (1998) p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. Ann Surg Oncol 5: 203-208.
19. Fu CG, Tominaga O, Nagawa H, Nita ME, Masaki T, et al. (1998) Role of p53 and p21/WAF1 detection in patient selection for preoperative radiotherapy in rectal cancer patients. Dis Colon Rectum 41: 68-74.
20. Dworak O, Keilholz L, Hoffmann A, (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12: 19-23.
21. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, et al. (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23: 8688-8696.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
23. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, et al. (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73: 2680-2686.
24. Edge SB, Compton CC, (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17: 1471-1474.
25. JapaneseSocietyforCanceroftheColonandRectum (1994) Criteria for histopathological evaluation of radiotherapy effect. In: General roles for clinical and pathological studies on cancer of the colon, rectum and anus 5th ed Tokyo: Kanehara & Co,: 42.
26. Elsaleh H, Robbins P, Joseph D, Powell B, Grieu F, et al. (2000) Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer? Radiother Oncol 56: 239-244.
27. Kelley ST, Coppola D, Yeatman T, Marcet J, (2005) Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways. Clin Colorectal Cancer 5: 114-118.
28. Scott N, Hale A, Deakin M, Hand P, Adab FA, et al. (1998) A histopathological assessment of the response of rectal adenocarcinoma to combination chemo-radiotherapy: relationship to apoptotic activity, p53 and bcl-2 expression. Eur J Surg Oncol 24: 169-173.
29. Wheeler JM, Warren BF, Mortensen NJ, Ekanyaka N, Kulacoglu H, et al. (2002) Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. Dis Colon Rectum 45: 1051-1056.
30. Moral M, Fdez-Acenero MA, Cuberes R, Suarez A, (2009) Factors influencing histological response after neoadjuvant chemoradiation therapy for rectal carcinoma. Pathol Res Pract 205: 695-699.
31. Jakob C, Liersch T, Meyer W, Becker H, Baretton GB, et al. (2008) Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. World J Gastroenterol 14: 1060-1066.
32. Zlobec I, Vuong T, Compton CC, Lugli A, Michel RP, et al. (2008) Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. Br J Cancer 98: 450-456.
33. Negri FV, Campanini N, Camisa R, Pucci F, Bui S, et al. (2008) Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer 98: 143-147.
34. Terzi C, Canda AE, Sagol O, Atila K, Sonmez D, et al. (2008) Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Int J Colorectal Dis 23: 37-45.
35. Kobayashi H, Hashiguchi Y, Ueno H, Shinto E, Kajiwara Y, et al. (2007) Absence of cyclooxygenase-2 protein expression is a predictor of tumor regression in rectal cancer treated with preoperative short-term chemoradiotherapy. Dis Colon Rectum 50: 1354-1362.
36. Takeuchi K, Nakajima M, Miyazaki T, Ide M, Asao T, et al. (2007) Is p53 and heat shock protein 70 expression a useful parameter for preoperative hyperthermoradiation therapy in advanced rectal carcinoma. Hepatogastroenterology 54: 367-372.
37. Sadahiro S, Suzuki T, Maeda Y, Tanaka Y, Nakamura T, et al. (2007) Predictors of tumor downsizing and regression with preoperative radiotherapy alone and with concomitant tegafur/uracil (UFT) for resectable advanced rectal adenocarcinoma. Hepatogastroenterology 54: 1107-1112.
38. Lopez-Crapez E, Bibeau F, Thezenas S, Ychou M, Simony-Lafontaine J, et al. (2005) p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis. Br J Cancer 92: 2114-2121.
39. Komuro Y, Watanabe T, Tsurita G, Muto T, Nagawa H, (2005) Evaluating the combination of molecular prognostic factors in tumor radiosensitivity in rectal cancer. Hepatogastroenterology 52: 666-671.
40. Suzuki T, Sadahiro S, Fukasawa M, Ishikawa K, Kamijo A, et al. (2004) Predictive factors of tumor shrinkage and histological regression in patients who received preoperative radiotherapy for rectal cancer. Jpn J Clin Oncol 34: 740-746.
41. Charara M, Edmonston TB, Burkholder S, Walters R, Anne P, et al. (2004) Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res 24: 3161-3167.
42. Diez M, Ramos P, Medrano MJ, Muguerza JM, Villeta R, et al. (2003) Preoperatively irradiated rectal carcinoma: analysis of the histopathologic response and predictive value of proliferating cell nuclear antigen immunostaining. Oncology 64: 213-219.
43. Saw RP, Morgan M, Koorey D, Painter D, Findlay M, et al. (2003) p53, deleted in colorectal cancer gene, and thymidylate synthase as predictors of histopathologic response and survival in low, locally advanced rectal cancer treated with preoperative adjuvant therapy. Dis Colon Rectum 46: 192-202.
44. Komuro Y, Watanabe T, Hosoi Y, Matsumoto Y, Nakagawa K, et al. (2003) Prediction of tumor radiosensitivity in rectal carcinoma based on p53 and Ku70 expression. J Exp Clin Cancer Res 22: 223-228.
45. Rebischung C, Gerard JP, Gayet J, Thomas G, Hamelin R, et al. (2002) Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer 100: 131-135.
46. Rodel C, Grabenbauer GG, Papadopoulos T, Bigalke M, Gunther K, et al. (2002) Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. Int J Radiat Oncol Biol Phys 52: 294-303.
47. Nasierowska-Guttmejer A, (2001) The comparison of immunohistochemical proliferation and apoptosis markers in rectal carcinoma treated surgically or by preoperative radio-chemotherapy. Pol J Pathol 52: 53-61.
48. Sakakura C, Koide K, Ichikawa D, Wakasa T, Shirasu M, et al. (1998) Analysis of histological therapeutic effect, apoptosis rate and p53 status after combined treatment with radiation, hyperthermia and 5-fluorouracil suppositories for advanced rectal cancers. Br J Cancer 77: 159-166.
49. Spitz FR, Giacco GG, Hess K, Larry L, Rich TA, et al. (1997) p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer. Clin Cancer Res 3: 1685-1690.
50. Smith FM, Reynolds JV, Miller N, Stephens RB, Kennedy MJ, (2006) Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol 32: 55-64.